GlassScriptPhysician profile
Nwamaka Dike
NPI 1144858143
$1,320.26
in general payments reported to CMS, 2019-2025
21 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $912 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $242.04 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $127.39 | 2024-2025 | |
| Lilly USA, LLC | $124.93 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $98.64 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $77.30 | 2024 | Farxiga, Airsupra, Breztri |
| Sumitomo Pharma America, INC. | $70.90 | 2024-2025 | Gemtesa |
| Amgen INC. | $65.49 | 2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $65.08 | 2024-2025 | |
| Procept Biorobotics Corporation | $56.03 | 2024 | Aquabeam System |
| Phathom Pharmaceuticals, INC. | $54.60 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.33 | 2024 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $44.71 | 2025 | |
| Janssen Pharmaceuticals, INC | $37.63 | 2024 | Spravato |
| Merck Sharp & Dohme LLC | $36.56 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Nevro Corp. | $32.27 | 2024 | Senza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.11 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $27.96 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $26.62 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.00 | 2024 | Caplyta |
| Currax Pharmaceuticals LLC | $16.69 | 2024 | Contrave |
| Glaxosmithkline, LLC. | $13.98 | 2024 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nwamaka Dike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.